Table 2 Baseline characteristics of the Dat’Aids sample of patients
N = 27,341 | ||||
|---|---|---|---|---|
Mean | SD | 95% bca CI | ||
Age | Years | 49.43 | 11.37 | [49.29; 49.55] |
Duration of the current treatment | Years | 8 | 5.26 | [7.94; 8.07] |
Duration of the HIV infection | Years | 30.96 | 17.09 | [30.63; 31.06] |
N | % | |||
Country of birth | France | 11,290 | 41 | |
Other | 16,051 | 59 | ||
Gender | Male | 18,880 | 69 | |
Female | 8461 | 31 | ||
Transmission mode | MSM | 10,610 | 39 | |
Other | 16,731 | 61 | ||
Cardiovascular disease | Yes | 8693 | 32 | |
No | 18,648 | 68 | ||
Diabetes | Yes | 1544 | 6 | |
No | 25,797 | 94 | ||
AIDS diagnosis | Yes | 6633 | 24 | |
No | 20,708 | 76 | ||
Creatinine clearance (mL / min / 1.73 m2) | Low (≤ 29) | 214 | 1 | |
Medium (> 29 and ≤ 89) | 14,457 | 53 | ||
High (> 89) | 12,670 | 46 | ||
HIV RNA (viral load, in copies / mL) | Low (≤ 50) | 25,294 | 92 | |
Medium (> 50 and ≤ 10,000) | 1619 | 6 | ||
High (> 10,000) | 428 | 2 | ||